Press Release: Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today presented positive results from the Phase 1 healthy participant study of CDX-622, a novel, bispecific antibody that targets soluble SCF and TSLP, at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. Data demonstrated that CDX-622 induced rapid, durable, dose-dependent…
Bank of Spain-regulated card issuer combines human-led and agentic AI pentesting to surface business logic risk and meet regulatory traceability requirements Bank of Spain-regulated card issuer combines human-led and agentic AI pentesting to surface business logic risk and meet regulatory traceability requirements
Þann 12. mars 2026 var tilkynnt um undirritun Sýnar hf. (Sýn) og Ása hf. (Ása) á skilmálaskjali um kaup Ása á vef- og útvarpsmiðlum Sýnar. Frestur samkvæmt skilmálaskjalinu til að ljúka gerð endanlegs kaupsamnings og annarrar nauðsynlegrar skjalagerðar er nú liðinn án þess að kaupsamningur hafi verið undirritaður. Samkomulag um einkarétt Ása til samningaviðræðna er…
